Search
Potassium
go.drugbank.com/drugs/DB14500ApprovedInvestigationalThey are available in an assortment of tablet, injection, and other forms, depending on the setting and condition being treated. … Potassium is often a key ingredient for intravenous fluids, given to patients in clinical settings for rehydration, nutrition, and replenishment of electrolytes.
Mixtures: Multi II IV Vi Tab, Vc IIHelium
go.drugbank.com/drugs/DB09155ApprovedInvestigationalVet approvedIts boiling and melting points are the lowest among all the elements. Its clinical benefit in inhalation therapy arises from its advantageous physical properties than ambient air. … It is also used as an analytical reagent in diagnostic/imaging tests to detect respiratory function of the patient.
Mixtures: Oxygen In Helium Mix, Oxygen In Helium MixtureAmivantamab
go.drugbank.com/drugs/DB16695ApprovedInvestigationalFDA approved the subcutaneous formulation, RYBREVANT FASPRO™, across all existing and expanded indications of amivantamab, including its use as a first-line, chemotherapy-free combination regimen with … [A235103,A235123] Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and were generally treated with platinum-based therapy.
Osimertinib
go.drugbank.com/drugs/DB09330ApprovedInvestigationalIn contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. … [A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved
Synonyms: N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamidePhenazopyridine
go.drugbank.com/drugs/DB01438ApprovedInvestigationalIn the USA, this drug was previously marked by Roche but has been discontinued by the FDA.[L7832] It is still used in various parts of the world. … Ingestion of phenazopyridine is found to change the appearance of the urine by imparting an orange or red color, as it is considered an azo dye.[L7829]
Mixtures: All-In-One UTI Emergency Kit, All-In-One UTI Emergency KitBelumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines … [L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925]
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A198963] Infitratinib is a pan-FGFR inhibitor, as it is an ATP-competitive inhibitor of all four FGFR receptor subtypes. … difficulties and commercial infeasibility in continuing drug distribution.
Belinostat
go.drugbank.com/drugs/DB05015ApprovedInvestigationalThe safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. … It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma.
Synonyms: (2E)-N-HYDROXY-3-(3-(PHENYLSULFAMOYL)PHENYL)PROP-2-ENAMIDE, N-Hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamideEconazole
go.drugbank.com/drugs/DB01127ApprovedIt is used topically in dermatomycoses also orally and parenterally.
Sunitinib
go.drugbank.com/drugs/DB01268ApprovedInvestigationalIn addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3. … These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R).